Dropbox Inc vs Merck & Co., Inc. — how do they compare? Dropbox Inc trades at $33.51 (market cap $7.41B), while Merck & Co., Inc. trades at $130.01 (market cap $321.77B). The key difference: Merck & Co., Inc. is far larger — about 43.4× Dropbox Inc's market cap, and Merck & Co., Inc. pays a 2.61% dividend while Dropbox Inc pays none. Which is the better fit depends on your goals.
| DBX | MRK | |
|---|---|---|
Market Cap | $7.41B | $321.77B |
Sector | Technology | Health |
52-Week High | $35.00 | $131.84 |
52-Week Low | $22.06 | $77.60 |
Enterprise Value | $10.27B | $368.53B |
Dividend Yield | — | 2.61% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Merck (MRK) trades at $130.90, up 1.81% on the day, with a bullish technical outlook and strong institutional support. Recent earnings beats in Q4 2025 and Q1-Q2 2026, alongside a 28.07% net income margin in 2025, highlight operational strength. The acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline, though a high P/E of 104.74 signals premium valuation. Cash flow remains positive at $1.37B in 2025, but investing outflows have increased.
The stock offers growth potential from pipeline expansion and analyst consensus targeting $140.36, but risks include elevated debt-to-asset ratios (36.06% in 2025) and competitive pressures. Investors should weigh robust profitability against valuation concerns and macroeconomic headwinds affecting the pharma sector.
Trailing returns across standard periods
Latest headlines on both assets
Dropbox is a leading provider of cloud-storage and content collaboration tools with an emphasis on individuals and SMB. The company was founded in 2007 and was a pioneer in cloud storage and cross-platform file syncing. Utilizing inorganic and organic means, the firm has been working on diversifying its product mix and pivoting away from the cloud-storage space.
Read more on DBX →Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →